Dr Elena Kowalski, MSc, PhD
Molecular Biology and Immunology — Imperial College London
Profile last reviewed: 2026-05-20
Dr Kowalski specialises in immune peptide research, with publications on thymosin alpha-1 and antimicrobial peptides. She reviews our immunology content and ensures our safety information reflects current research.
Credentials
- MSc, Molecular Biology
- PhD, Molecular Biology — Imperial College London
- Published research on thymosin alpha-1 and antimicrobial peptides
Professional registrations
- Royal Society of Biology: Member
- British Society for Immunology: Member
Academic and learned-society registrations only. No clinical prescribing registration applies to this reviewer's role.
Role on the editorial board
Lead reviewer for immune-modulating and antimicrobial peptide content. Reviews thymosin family, LL-37, KPV, defensins, and related immunology claims across the peptide library and the immune-and-inflammation hub.
Conflict of interest disclosures
- No equity in peptide manufacturers, immunology-product companies, or online clinics.
- No paid consulting arrangements with companies that market the peptides reviewed.
- Has received public-sector research funding (UKRI / Wellcome) for unrelated immunology work; disclosed transparently.
Disclosures are reviewed annually and updated at the date shown above. See the conflict-of-interest policy for the wider framework.
Sections reviewed
- All immune-modulating peptide profiles (thymosin alpha-1, LL-37, KPV, defensins, etc.)
- Immune and Inflammation hub and spokes
- Autoimmune-conditions and long-COVID guides
Citation policy
Immunology claims must trace to peer-reviewed literature. Mechanism claims are clearly separated from clinical-outcome claims. Where licensed-medicine evidence exists in non-UK markets (e.g. thymosin alpha-1 in parts of Europe), the regulatory boundary is stated explicitly.
The site-wide methodology is documented in our evidence grading methodology and editorial standards.
About the editorial board
Peptide Authority’s editorial board is responsible for the accuracy, evidence-grading, and UK regulatory framing of the content on this site. Read more about how we work in editorial standards and the corrections policy.
Other reviewers
- Dr Sarah Mitchell, PhD — Pharmacology and Peptide Therapeutics
- Dr James Harrington, MBChB, MRCP — Clinical Endocrinology
- Dr David Chen, PharmD — Clinical Pharmacy and Regulatory Affairs